RxDoctor Payments Data

Jared Nielsen

Ophthalmology · West Des Moines, IANPI 1467409383

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Genentech USA, Inc. at 31.4% of the total. Reporting peaked in 2023 at $39,771 and has fallen 69.8% since, to $12,003 in 2024. Among ophthalmology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$116,548in general payments, 2019–2025

Across 104 payments — averaging $1120.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$37K
  • Apellis Pharmaceuticals, Inc.$33K
  • Novartis$11K
  • Regeneron Healthcare Solutions, Inc.$9K
  • Novartis Pharma AG$5K
  • Astellas Pharma US Inc$5K
  • plus $17K from 13 others
$3,023,111in research payments, 2019–2025

Across 215 payments — averaging $14,061 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$1.9M
  • Novartis$734K
  • Regeneron$270K
  • Bayer$34K
  • AstraZeneca$25K
  • F. Hoffmann-la Roche AG$21K
  • plus $15K from 3 others

What the payments were for

  • Consulting fees$68,48659%
  • Speaking & faculty fees$33,28529%
  • Travel & lodging$8,0167%
  • Food & beverage$3,0313%
  • Ownership interest$2,5812%
  • Other$1,1501%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,548 in reported general payments places this provider in the 95th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$937,214
Medicare patients
304
Services billed
20,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate43$2,333
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat30$420
MoxifloxacinMoxifloxacin Hcl15$313
Brimonidine Tartrate19$181
Latanoprost22$157

Paid to pharmacies, not to this prescriber.

Other ophthalmology in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →